A real world multicenter retrospective study on extramedullary disease from Balkan Myeloma Study Group and Barcelona University: analysis of parameters that improve outcome.
Journal
Haematologica
ISSN: 1592-8721
Titre abrégé: Haematologica
Pays: Italy
ID NLM: 0417435
Informations de publication
Date de publication:
01 2020
01 2020
Historique:
received:
11
02
2019
accepted:
05
07
2019
pubmed:
7
7
2019
medline:
28
4
2021
entrez:
7
7
2019
Statut:
ppublish
Résumé
Here, we report the outcome of 226 myeloma patients presenting with extramedullary plasmacytoma or paraosseous involvement in a retrospective study conducted in 19 centers from 11 countries. Extramedullary disease was detected at diagnosis or relapse between January 2010 and November 2017. Extramedullary plasmacytoma and paraosseous involvement were observed in 130 patients at diagnosis (92 of 38) and in 96 at relapse (84 of 12). The median time from multiple myeloma diagnosis to the development of extramedullary disease was 25.1 months (range 3.1-106.3 months) in the relapse group (median follow up: 15 months). Imaging approach for extramedullary disease was computed tomography (n=133), positron emission tomography combined with computed tomography (n=50), or magnetic resonance imaging (n=35). The entire group received a median two lines of treatment and autologous stem cell transplantation (44%) following the diagnosis of extramedullary disease. Complete response was higher for paraosseous involvement
Identifiants
pubmed: 31278209
pii: haematol.2019.219295
doi: 10.3324/haematol.2019.219295
pmc: PMC6939516
doi:
Types de publication
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
201-208Commentaires et corrections
Type : ErratumIn
Informations de copyright
Copyright© 2020 Ferrata Storti Foundation.
Références
Eur J Haematol. 2006 May;76(5):405-8
pubmed: 16529604
Haematologica. 2018 May;103(5):890-897
pubmed: 29419433
Blood. 2008 Mar 1;111(5):2516-20
pubmed: 17975015
Haematologica. 2012 Nov;97(11):1761-7
pubmed: 22689675
Ann Oncol. 2010 Feb;21(2):325-30
pubmed: 19633044
Ann Intern Med. 1989 Apr 1;110(7):521-5
pubmed: 2647015
N Engl J Med. 2011 Mar 17;364(11):1046-60
pubmed: 21410373
Leukemia. 2005 Sep;19(9):1702-4
pubmed: 16001088
Br J Haematol. 2016 Dec;175(5):884-891
pubmed: 27682187
J Clin Oncol. 1994 Nov;12(11):2398-404
pubmed: 7964956
Adv Ther. 2011 Nov;28 Suppl 7:1-6
pubmed: 22105527
Leukemia. 2015 Nov;29(11):2119-25
pubmed: 26265183
J Clin Oncol. 2011 Oct 1;29(28):3805-12
pubmed: 21900099
J Hematol Oncol. 2018 Jan 16;11(1):10
pubmed: 29338789
Leuk Lymphoma. 2013 Jun;54(6):1135-41
pubmed: 23210572
Lancet Oncol. 2014 Nov;15(12):e538-48
pubmed: 25439696
Bone Marrow Transplant. 2017 Oct;52(10):1473-1475
pubmed: 28805789
Br J Haematol. 2015 Jun;169(6):843-50
pubmed: 26032514
Br J Haematol. 1996 May;93(2):345-51
pubmed: 8639427
Blood. 2016 Feb 25;127(8):971-6
pubmed: 26679866
Haematologica. 2005 Feb;90(2):278-9
pubmed: 15710593
Haematologica. 2014 Feb;99(2):360-4
pubmed: 24038024
Br J Haematol. 2001 May;113(2):422-4
pubmed: 11380408
Blood. 2012 Aug 23;120(8):1589-96
pubmed: 22791289
Leuk Lymphoma. 2004 Nov;45(11):2275-9
pubmed: 15512817
Haematologica. 2004 Jul;89(7):832-6
pubmed: 15257935
Br J Haematol. 2015 Jun;169(6):851-8
pubmed: 25833301
Ann Hematol. 2012 Jul;91(7):1031-7
pubmed: 22286070
Blood. 2016 Jun 16;127(24):2955-62
pubmed: 27002115